Information de reference pour ce titreAccession Number: | 00137700-201303000-00002.
|
Author: | Park, Joong-Won 1; Amarapurkar, Deepak 2; Chao, Yee 3; Chen, Pei-Jer 4; Geschwind, Jean-Francois H. 5; Goh, Khean Lee 6; Han, Kwang-Hyub 7; Kudo, Masatoshi 8; Lee, Han Chu 9; Lee, Rheun-Chuan 10; Lesmana, Laurentius A. 11; Lim, Ho Yeong 12; Paik, Seung Woon 13; Poon, Ronnie T 14; Tan, Chee-Kiat 15; Tanwandee, Tawesak 16; Teng, Gaojun 17; Cheng, Ann-Lii 18,
|
Institution: | (1)Centre for Liver Cancer, National Cancer Center Hospital, Seoul, Korea (2)Department of Gastroenterology, Bombay Hospital and Medical Research Centre, Mumbai, India (3)Division of Chemoradiotherapy, Cancer Centre Taipei Veterans General Hospital, Taipei, Taiwan (4)Graduate Institute of Clinical Medicine, College of Medicine, Taiwan National University, Taipei, Taiwan (5)Johns Hopkins University School of Medicine, Baltimore, USA (6)Division of Gastroenterology, Department of Medicine, University of Malaya, Kuala Lumpur, Malaysia (7)Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea (8)Department of Hepatology and Gastroenterology, Kinki University School of Medicine, Osaka-Sayama, Japan (9)Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea (10)Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan (11)Hepatology Section, Department of Internal Medicine, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia (12)Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Seoul, Korea (13)Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea (14)Department of Surgery, Queen Mary Hospital, University of Hong Kong, Hong Kong (15)Department of Gastroenterology and Hepatology, Singapore General Hospital, Singapore (16)Division of Gastroenterology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand (17)Department of Radiology, Zhong-Da Hospital, Southeast University, Nanjing, China (18)Department of Oncology and Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
|
Title: | |
Source: | Liver International. 33(3):327-337, March 2013.
|
Abstract: | : Hepatocellular carcinoma (HCC) presents with a high burden of disease in East Asian countries. Intermediate-stage HCC as defined by the Barcelona Clinic Liver Cancer (BCLC) staging system poses a clinical challenge as it includes a heterogeneous population of patients that can vary widely in terms of tumour burden, liver function and disease aetiology. Intermediate HCC patients often have unsatisfactory clinical outcomes with repeated transarterial chemoembolization (TACE, due to non-response of the target tumour or the development of further metastasis indicating progressive disease. In September 2011, an Expert Panel Opinion on Interventions in Hepatocellular Carcinoma (EPOIHCC) was convened in HK in an attempt to provide a consensus on the practice of TACE. To that end, current clinical practice throughout Asia was reviewed in detail including safety and efficacy data on TACE alone as well as in combination with targeted systemic therapies. This review summarises the evidence discussed at the meeting and provides expert recommendation regarding the available therapeutic options for unresectable intermediate stage HCC. A key consensus of the Expert Panel was that in order to improve patient outcomes and long-term survival, the possibility of using TACE in combination with targeted agents given systemically should be explored. While the currently available clinical data is promising, the expected completion of several pivotal phase II and III RCTs will provide further evidence in support of the rationale for combination therapy regimens.
Copyright (C) 2013 Blackwell Publishing Ltd.
|
Author Keywords: | Combination therapy; Hepatocellular carcinoma; Sorafenib; TACE .
|
References: | 1. GLOBOCAN, International Agency for Cancer Research. 2008 Available at http://www-dep.iarc.fr- ouverture dans une nouvelle fenêtre. Accessed 20 November, 2011.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
4. Piscaglia F, Bolondi L. The intermediate hepatocellular carcinoma stage: should treatment be expanded? Dig Liver Dis 2010; 42(Suppl. 3): S258-63.
5. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19: 329-38.
6. Llovet JM, Di Bisceglie AM, Bruix J, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008a; 100: 698-711.
7. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-30.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
9. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
10. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl. 1): S179-88.
11. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362: 1907-17.
12. Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33: 541-51.
13. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-47.
14. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003; 37: 429-42.
15. Oliveri RS, Wetterslev J, Gluud C. Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma. Cochrane Database Syst Rev 2011 (3): CD004787.
16. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-55.
17. Lin DY, Liaw YF, Lee TY, Lai CM. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma-a randomized controlled trial. Gastroenterology 1988; 94: 453-6.
18. Peck-Radosavljevic M, Sieghart W, Kolblinger C, et al. Austrian Joint OGGH-OGIR-OGHO-ASSO position statement on the use of transarterial chemoembolization (TACE) in hepatocellular carcinoma. Wien Klin Wochenschr 2012; 124: 104-10.
19. Antoch G, Roelle G, Ladd SC, et al. Selective and sequential transarterial chemoembolization: survival in patients with hepatocellular carcinoma. Eur J Radiol 2012; 81: 2290-7.
20. Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30: 6-25.
21. Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol 2012; 56: 1330-5.
22. Camma C, Schepis F, Orlando A, et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002; 224: 47-54.
23. Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 2007; 46: 474-81.
24. Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33: 41-52.
25. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer 2010; 116: 1305-14.
26. D'Avola D, Lnarrairaegui M, Bilbao JI, et al. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. Hepatogastroenterology 2009; 56: 1683-8.
27. Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011; 54: 868-78.
28. Inarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21: 1205-12.
29. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL. A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 2002; 94: 1747-52.
30. Sangro B, Inarrairaegui M, Bilbao JI. Radioembolization for hepatocellular carcinoma. J Hepatol 2012; 56: 464-73.
31. Prompers L, Bucerius J, Brans B, et al. Selective internal radiation therapy (SIRT) in primary or secondary liver cancer. Methods 2011; 55: 253-7.
32. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
33. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008b; 359: 378-90.
34. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
35. Molinari M, Kachura JR, Dixon E, et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American cancer centre. Clin Oncol (R Coll Radiol) 2006; 18: 684-92.
36. Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359: 1734-9.
37. Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35: 1164-71.
38. Lin CI, Lin ZY, Hsieh MY, et al. Potential risk factors for the reactivation of the replication of hepatitis B and C viruses after transcatheter arterial chemoembolization of hepatocellular carcinoma. Kaohsiung J Med Sci 2011; 27: 554-9.
39. Jang JW, Choi JY, Bae SH, et al. Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinoma. J Hepatol 2004; 41: 427-35.
40. Peng JW, Lin GN, Xiao JJ, Jiang XM. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy. Asia Pac J Clin Oncol 2013; 8: 356-61.
41. Ikeda K, Arase Y, Kobayashi M, et al. Hepatitis B virus-related hepatocellular carcinogenesis and its prevention. Intervirology 2005; 48: 29-38.
42. EASL-EORTC clinical practice guidelines. management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
43. Chin PL, Chu DZ, Clarke KG, et al. Ethnic differences in the behavior of hepatocellular carcinoma. Cancer 1999; 85: 1931-6.
44. Takayasu K, Arii S, Ikai I, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006; 131: 461-9.
45. Shi M, Chen JA, Lin XJ, et al. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16: 264-9.
46. Cheng HY, Wang X, Chen D, Xu AM, Jia YC. The value and limitation of transcatheter arterial chemoembolization in preventing recurrence of resected hepatocellular carcinoma. World J Gastroenterol 2005; 11: 3644-6.
47. Kasai K, Ushio A, Sawara K, et al. Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol 2010; 16: 3437-44.
48. Seki A, Hori S, Kobayashi K, Narumiya S. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol 2011; 34: 557-65.
49. Kim HW, Park JW, Park HK, et al. Outcome of transarterial chemoembolization in Korean patients with hepatocellular carcinoma: reference for a prospective combination study with molecular targeted agents. Hepatology 2010; 52(suppl): 1183A.
50. Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev 2011; 37: 212-20.
51. Satake M, Uchida H, Arai Y, et al. Transcatheter arterial chemoembolization (TACE) with lipiodol to treat hepatocellular carcinoma: survey results from the TACE study group of Japan. Cardiovasc Intervent Radiol 2008; 31: 756-61.
52. Park JW, Kim HW, Chen PJ, et al. Observations of HCC management patterns from the global HCC BRIDGE study: an interim analysis from a south Korean referral center. APASL 9th Single Topic Conference. 2011; GS3-4.
53. Kim HY, Park JW, Joo J, et al. Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol 2011; 27: 1051-6.
54. Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 34: 205-13.
55. Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with Drug-Eluting Beads for hepatocellular carcinoma. J Clin Oncol 2011; 29: 3960-7.
56. Park JW, Koh YH, Kim HB, et al. , Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 2012; 56: 1336-42.
57. Chung YH, Han G, Yoon JH, et al. Interim analysis of start: Study in asia of the combination of TACE (Transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer 2012; doi: 10.1002/ijc.27925.
58. Lencioni R, Llovet JM, Han G, et al. , Sorafenib or placebo in combination with transarterial chemoembolization (TACE) with doxorubicin-eluting beads (DEBDOX) for intermediate-stage hepatocellular carcinoma (HCC): phase II, randomized, double-blind SPACE trial. J Clin Oncol 2012. 30(4 suppl): Abstract LBA 154.
59. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-14.
60. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.
61. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; 47: 2117-27.
62. Sansonno D, Lauletta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist 2012; 17: 359-66.
63. Sieghart W, Pinter M, Reisegger M, et al. Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol 2012; 22: 1214-23.
64. Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma. BMC Cancer 2012; 12: 263.
65. Erhardt A, Kolligs FT, Dollinger M, et al. Sorafenib plus TACE for the treatment of advanced Hepatocellular carcinoma - final results of the SOCRATES trial. J Hepatol 2011; 54: S25-44.
|
Language: | English.
|
Document Type: | Consensus.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1478-3223
|
NLM Journal Code: | 101160857
|
DOI Number: | https://dx.doi.org/10.1111/liv.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|